ArticleJournal of neurochemistry2025
Taurine Intake, Plasma Taurine Concentration, and Dementia Risk: Findings From the Malmö Diet and Cancer Study.
Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Taurine as an Early-Phase Disease-Modifying Candidate for Alzheimer's Disease.International journal of molecular sciences · 2026Review
- Taurine Intake, Plasma Taurine Concentration, and Dementia Risk: Findings From the Malmö Diet and Cancer Study.Journal of neurochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Preclinical studies suggest that taurine may exert neuroprotective effects. However, its relevance to dementia risk in human populations remains unclear. We investigated the associations between mid-life dietary taurine intake, circulating taurine concentrations, and the risk of late-life all-cause dementia, Alzheimer's disease (AD), and vascular dementia (VaD) in a large prospective cohort. This study utilized data from 27 786 participants of the Malmö Diet and Cancer Study with baseline examination from 1991 to 1996. Dietary taurine intake was estimated from a detailed diet history and adjusted for energy intake. Plasma taurine concentration was measured in a subset of 3693 individuals. Dementia diagnoses were ascertained through the Swedish National Patient Register and validated by memory clinic physicians. Cox proportional hazards models assessed associations with dementia risk, adjusting for potential confounders including APOE ε4 status, lifestyle factors, and comorbidities. Over a median 25-year follow-up, 3224 participants developed dementia. No significant associations were found between dietary taurine intake or plasma taurine concentrations and the risk of all-cause dementia, AD, or VaD. Circulating taurine concentrations were only weakly correlated with dietary intake, suggesting a predominant role of endogenous taurine synthesis and metabolism. Our findings fail to support a protective role for taurine intake against dementia in humans. Further studies are warranted to examine potential effects under specific pathological conditions or with high-dose supplementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.